Litigation of unlicensed US stem cell products
Cell Stem Cell · 2025
DOI: 10.1016/j.stem.2025.04.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Stem Cell, 2025. Verfasst von Branden Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA; Department of Orthopaedic Surgery, The Johns Hopkins Hospital,…. Hauptthemen laut MEDLINE: Stem Cells, Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Financial dispositions against unapproved stem cell interventions have grown significantly, with successful class-action lawsuits, malpractice claims, and collaborative prosecutions between government agencies. In addition to improved dispositions, federal circuit courts have given unanimous affirmation to the FDA's regulatory authority over stem cell interventions, establishing critical precedents for oversight.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA; Department of Orthopaedic Surgery, The Johns Hopkins Hospital, 601 N. Caroline Street, Suite 5251, Baltimore, MD 21287, USA.
- Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA.
- Department of Orthopaedic Surgery, The Johns Hopkins Hospital, 601 N. Caroline Street, Suite 5251, Baltimore, MD 21287, USA. Electronic address: alevin25@jhmi.edu.
Zitieren
APA
Lee, B., Brookes, N., & Levin, A. S. (2025). Litigation of unlicensed US stem cell products. Cell Stem Cell. https://doi.org/10.1016/j.stem.2025.04.001
Vancouver
Lee B, Brookes N, Levin AS. Litigation of unlicensed US stem cell products. Cell Stem Cell. 2025. doi:10.1016/j.stem.2025.04.001
BibTeX
@article{Lee2025,
author = {Lee, Branden and Brookes, Noah and Levin, Adam S},
title = {Litigation of unlicensed US stem cell products},
journal = {Cell Stem Cell},
year = {2025},
doi = {10.1016/j.stem.2025.04.001}
}
EUVIMED